Chronic use of intracerebral dialysis for the in vivo measurement of 3,4-dihydroxyphenylethylamine and its metabolite 3,4-dihydroxyphenylacetic acid.
The intracerebral dialysis technique was studied with a method in which the rat was directly connected to the HPLC equipment. The effect of three pharmacological treatments [perfusion of 60 mmol K+ or 5 X 10(-5) M (+)-amphetamine or subcutaneous injection of 2 mg/kg (+)-amphetamine] on the release of 3,4-dihydroxyphenylethylamine (dopamine) and 3,4-dihydroxyphenylacetic acid was followed over a period of 7 days. The marked rise of dopamine output seen after infusion of K+ had almost disappeared on day 3. Tissue reactions around the membrane presumably formed a barrier preventing K+ from reaching dopaminergic terminals. In contrast, the pronounced rise in dopamine level after amphetamine (infused as well as systemically administered) was still present (although diminished) 8 days after implantation. It is concluded that, with certain restrictions, brain dialysis of dopamine is still useful several days after implantation of the membrane.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000032:analysis*; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D003956:Dialysis / Q000379:methods; D004298:Dopamine / Q000032:analysis* / Q000378:metabolism; D008297:Male; D010648:Phenylacetates / Q000032:analysis*; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains
D010648:Phenylacetates; D015102:3,4-Dihydroxyphenylacetic Acid; D000661:Amphetamine; D011188:Potassium; D004298:Dopamine